Alembic Pharmaceuticals Limited receives USFDA Final Approval for Prucalopride Tablets
NiveshIQ
NSE: APLLTD · Pharma
Alembic Pharmaceuticals Ltd.
₹811.95▼ ₹6.90 (-0.84%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on APLLTD. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Alembic Pharmaceuticals Ltd.
Alembic Pharmaceuticals Limited (APLLTD) is an integrated pharmaceutical company that develops, manufactures, markets, and sells pharmaceutical products in India and internationally. The company generates revenue from various therapeutic areas, including cardiology, orthopaedics, anti-diabetic, ophthalmology, and others. In recent developments, Alembic Pharmaceuticals received USFDA Final Approval for Levothyroxine Sodium Tablets and reported a 29% rise in Q4 net profit to ₹203 Cr. However, the company's Q4 profit declined 59% YoY, leading to a 3% decline in shares. Despite this, Alembic Pharma targets double-digit growth as US momentum picks up, driven by its strong presence in the US market. The company's revenue stood at ₹7345 Cr, with a net income of ₹675 Cr. With a 'Buy' rating and a
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹6,229 Cr +10.20% | ₹6,673 Cr +7.10% | ₹7,345 Cr +10.10% |
| EBITDA Margin | 14.98% | 15.09% | 15.97% |
| Net Profit | ₹616.00 Cr +80.10% | ₹583.00 Cr -5.40% | ₹670.83 Cr +15.10% |
| EPS | ₹31.34 | ₹29.67 | ₹34.33 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Alembic Pharma: அமெரிக்காவில் புதிய மருந்துக்கு அனுமதி! ₹830 கோடி சந்தையில் நுழையும் நிறுவனம்!
Alembic Pharma Gets USFDA Approval for Prucalopride Tablets
🔒
+ 3 more stories about Alembic Pharmaceuticals Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q4FY26 results: revenue ₹1, 848 Cr, PAT ₹202 Cr, EPS ₹10.31, EBITDA margin 13.7%. Growth context: revenue YoY +4.4%, PAT YoY +28.4%, revenue QoQ -1.5%, PAT QoQ +52.7%. Street verdict: inline, revenue surprise -1.1%, PAT surprise -2.9%.
Management's emphasis on product launches, approvals, and therapy-mix improvement is expected to drive the next leg of g...
FY26 (last completed FY): revenue ₹7, 345 Cr, PAT ₹671 Cr, EBITDA margin 16.0%, EPS ₹34.33. Year-on-year: revenue YoY +1...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for APLLTD
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track APLLTD alongside your other holdings
Unlock full APLLTD research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Alembic Pharmaceuticals Ltd.?
NiveshIQ detects active intelligence signals for Alembic Pharmaceuticals Ltd. (APLLTD) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Alembic Pharmaceuticals Ltd.?
Alembic Pharmaceuticals Ltd. operates in the Pharma sector with a market capitalisation of ₹1,546,755.3L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.